scholarly journals The Evaluation of PSA levels in Libyan Prostate Cancer Patients

2022 ◽  
Vol 3 (1) ◽  
pp. 01-05
Author(s):  
Omar Alqawi ◽  
Eman Elshahmi ◽  
Fatma Emaetig ◽  
Fauzia Elgaraboli ◽  
Abubaker Abushnaf
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Specific Antigen ◽  
Developed Countries ◽  
P Value ◽  
Prostate Cancer Mortality ◽  
Psa Testing ◽  
The Developed Countries ◽  
The Relationship

Background: Prostate cancer is the second most frequent cancer and the fifth leading cause of cancer death in men with higher prevalence in the developed countries. The use of biomarkers for prostate cancer can improve the diagnosis of prostate cancer and clinical management of the patients. Prostate-specific antigen (PSA) is widely used to screen for prostate cancer and there is evidence that PSA testing reduces prostate cancer mortality. Objective: In this report we have studied the relationship between the Gleason score, age and PSA levels of prostate adenocarcinoma tissues from Libyan patients to evaluate the levels of PSA in prostate cancer patients. Materials and methods: The data was collected from medical files of 40 patients who underwent curative surgical prostatectomy or prostate true cut biopsy at National Cancer Institute (NCI)-Misurata, Libya during 2016 to 2018. The clinical and histopathological information included age, PSA levels, and Gleason score grade. Results: Our data showed that PSA level was statistically significant correlation with Gleason score grade (p- value = 0.007, <0.05). The increased serum PSA level was associated with the progression of prostate cancer. However, we found no statistically significant correlation between PSA and the age of patients (p- value = 0.435). Conclusion: Our data confirmed the association of high levels of PSA and the progress of prostate cancer.

The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels

The Prostate ◽  
2015 ◽  
Vol 75 (10) ◽  
pp. 1034-1042 ◽  
Author(s):  
Kouji Izumi ◽  
Hiroko Ikeda ◽  
Aerken Maolake ◽  
Kazuaki Machioka ◽  
Takahiro Nohara ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Gleason Score ◽  
Tnm Classification ◽  
Specific Antigen ◽  
The Relationship

scholarly journals Association of Caveolin-1 Expression With Prostate Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 ◽  
Author(s):  
Pei Chen ◽  
Yu-ling Zhang ◽  
Bai Xue ◽  
Guo-ying Xu
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Intraepithelial Neoplasia ◽  
Clinicopathological Characteristics ◽  
Clinicopathological Feature ◽  
Caveolin 1 ◽  
The Relationship

PurposeThe prognostic value of caveolin-1 in prostate cancer remains uncertain. Hence, this meta-analysis was performed to evaluate the prognostic value of caveolin-1 in prostate cancer, as well as ascertain the relationship between caveolin-1 expression and clinicopathological characteristics of prostate cancer patients.MethodsThe PubMed, Embase, Chinese National Knowledge Infrastructure and Chinese Biology Medicine databases were electronically searched to retrieve published studies on caveolin-1 expression in prostate cancer. After study selection and data extraction, the meta-analysis was conducted using Review manager 5.3 software. Odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. Funnel plot was used to assess publication bias.ResultsA total of ten studies were enrolled, which included 3976 cases of prostate cancer, 72 cases of high-grade intraepithelial neoplasia (HGPIN), and 157 normal controls. Results of the meta-analysis showed that the positive rate of caveolin-1 expression in prostate cancer was 18.28 times higher than that in normal control (OR= 18.28, 95% CI: 9.02–37.04, p&lt;0.01), and 4.73 times higher than that in HGPIN (OR= 4.73, 95% CI: 2.38–9.42, p&lt;0.01). The relationship between caveolin-1 and clinicopathological characteristics of prostate cancer showed that the differences in caveolin-1 expression in patients with prostate-specific antigen (PSA) &gt;10 vs. ≤ 10 (OR=2.09, 95% CI: 1.35–3.22, p&lt;0.01), differentiation degree low vs. medium/high (OR=2.74, 95% CI: 1.84–4.08, p&lt;0.01), TNM stage T3+T4 vs. T1+T2 (OR=2.77, 95% CI: 1.78–4.29, p&lt;0.01), and lymph node metastasis present vs. absent (OR=2.61, 95% CI: 1.84–3.69, p&lt;0.01) were statistically significant. The correlation analysis between caveolin-1 and the survival time of patients with prostate cancer demonstrated that caveolin-1 was closely related to the prognosis of prostate cancer patients (HR=1.50, 95% CI: 1.28–1.76, p&lt;0.01).ConclusionCaveolin-1 is overexpressed in prostate cancer, which can serve as a risk factor and adverse clinicopathological feature of prostate cancer. Caveolin-1 can also predict poor survival in prostate cancer patients after radical prostatectomy.

Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial.

1997 ◽  
Vol 15 (4) ◽  
pp. 1465-1469 ◽  
Author(s):  
A V D'Amico ◽  
R Whittington ◽  
S B Malkowicz ◽  
D Schultz ◽  
J E Tomaszewski ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Gleason Score ◽  
Multivariable Analysis ◽  
Specific Antigen ◽  
Radical Retropubic Prostatectomy ◽  
Phase Iii ◽  
Psa Failure

PURPOSE A multivariable analysis to evaluate the potential clinical and pathologic factors that predict for early biochemical failure in patients with pathologically organ-confined and margin-negative disease was performed to define patients who may benefit from adjuvant therapy. PATIENTS AND METHODS Three hundred forty-one prostate cancer patients treated with a radical retropubic prostatectomy between January 1989 and June 1995 and found to have pathologically organ-confined and margin-negative disease comprised the study population. A logistic regression multivariable analysis to evaluate the predictive value of the preoperative prostate-specific antigen (PSA) level, pathologic (prostatectomy) Gleason score, and pathologic stage on PSA failure occurring during the first postoperative year was performed. RESULTS Predictors of PSA failure during the first postoperative year in patients with pathologically organ-confined disease included pathologic Gleason score > or = 7 (P = .0007) and preoperative PSA level greater than 10 (P < .0001). Corresponding 3-year freedom-from-PSA-failure rates for these pathologic organ-confined patients with both, one, or neither of these factors were 60%, 75% to 84%, and 95%, respectively (P < .0001). CONCLUSION Prostate cancer patients with pathologically organ-confined and margin-negative disease and a preoperative PSA level greater than 10 ng/mL or a pathologic Gleason score > or = 7 have significant decrements in short-term PSA-failure-free survival. Therefore, these patients should be considered for adjuvant therapy in the setting of a phase III clinical trial.

Clinical significance of plasma fibrinogen level in patients with prostate cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16077-e16077
Author(s):  
Xiao-Kun Ma ◽  
Jing-Yun Wen ◽  
Zhan-Hong Chen ◽  
Qu Lin ◽  
Xing Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Locally Advanced ◽  
Specific Antigen ◽  
Tnm Stage ◽  
Plasma Fibrinogen ◽  
T State ◽  
Coagulation Analyzer ◽  
Worse Prognosis

e16077 Background: Most of malignant tumor patients have hypercoagulable state with plasma fibrinogen (Fib) levels increased. In this study, we aimed to investigate correlation of plasma Fib with routine prognostic factors of prostate cancer patients, including Gleason score, prostate specific antigen (PSA), TNM 7th Stage. Methods: From January 2007 to December 2012, 107 patients with prostate cancer and 44 cases of benign prostatic hyperplasia (BPH) were included in our study. Automated coagulation analyzer was used to determine the plasma fibrinogen levels. Results: The patients presented a mean age of 70.6 years, a mean PSA level of 28.73 ng/ml, clinically localized prostate cancer in 47 cases, locally advanced condition in 27cases, and distant metastatic disease in 33 cases. The fibrinogen levels were increased in cancer patients compared to that in patients with BPH (P = 0.031). Higher fibrinogen levels related to metastasis, higher TNM stage and increased PSA (p = 0.000, 0.041 and 0.004 respectively). Fib levels were irrelevant to T state, N state, and Gleason score. Conclusions: Prostate cancer patients displayed increased Fib levels. Plasma Fib is significantly increased in patients with higher PSA level,worse TNM stage and distant metastasis. The patients with high Fib might presented relative worse prognosis and should be monitored closely. [Table: see text]

scholarly journals The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients

2009 ◽  
Vol 9 ◽  
pp. 1040-1045 ◽  
Author(s):  
Chad W. M. Ritenour ◽  
John T. Abbott ◽  
Michael Goodman ◽  
Naomi Alazraki ◽  
Fray F. Marshall ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Bone Scan ◽  
Stage Migration ◽  
Gleason Grade ◽  
Newly Diagnosed ◽  
High Gleason Score ◽  
Bone Scans ◽  
The Relationship

Utilization of nuclear bone scans for staging newly diagnosed prostate cancer has decreased dramatically due to PSA-driven stage migration. The current criteria for performing bone scans are based on limited historical data. This study evaluates serum PSA and Gleason grade in predicting positive scans in a contemporary large series of newly diagnosed prostate cancer patients. Eight hundred consecutive cases of newly diagnosed prostate cancer over a 64-month period underwent a staging nuclear scan. All subjects had histologically confirmed cancer. The relationship between PSA, Gleason grade, and bone scan was examined by calculating series of crude, stratified, and adjusted odds ratios with corresponding 95% confidence intervals. Four percent (32/800) of all bone scans were positive. This proportion was significantly lower in patients with Gleason score ≤7 (1.9%) vs. Gleason score ≥8 (18.8%,p< 0.001). Among patients with Gleason score ≤7, the rate of positive bones scans was 70-fold higher when the PSA was >30 ng/ml compared to ≤30 ng/ml (p< 0.001). For Gleason score ≥8, the rate was significantly higher (27.9 vs. 0%) when PSA was >10 ng/ml compared to ≤10 ng/ml (p= 0.002). The combination of Gleason score and PSA enhances predictability of bone scans in newly diagnosed prostate cancer patients. The PSA threshold for ordering bone scans should be adjusted according to Gleason score. For patients with Gleason scores ≤7, we recommend a bone scan if the PSA is >30 ng/ml. However, for patients with a high Gleason score (8–10), we recommend a bone scan if the PSA is >10 ng/ml.

Aspartyl (Asparaginyl) ß hydroxylase (AABH) as a serum bio-marker for prostate cancer to identify prostate cancer, regardless of PSA level.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 10-10
Author(s):  
Mahmood Moshiri ◽  
Kiarash Moshiri ◽  
Arsha Moshiri ◽  
Hassan Monhemi ◽  
Mohammad Hadi Sekhavati
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Sandwich Elisa ◽  
Specific Antigen ◽  
High Serum ◽  
Cancer Tissue ◽  
Serum Samples ◽  
Psa Testing ◽  
Detect Prostate Cancer

10 Background: Background: Prostate Specific Antigen (PSA) is a molecular marker of prostate cancer (PC). I most countries, standard of care suggests annual PSA testing in all men over 50 years of age; and for men at high risk, the test is recommended from 40 years of age. Due to low Specificity and low sensitivity of the PSA test, a large number of unnecessary biopsies occur every year. This low specificity can be due to the fact that PSA is found in both benign and malignant lesions of Prostate tissue. To date measurement of the percentage of free PSA, have resulted an small improvements in specificity of PSA testing. Thus, the development of a simple blood test to detect prostate cancer that exhibits higher specificity compared to PSA could have the potential of reducing biopsies performed due to false positive screening results and improve the quality of medical care. Methods: We have investigated the utility of aspartyl (asparaginyl) β-hydroxylase (AABH) as a prostate cancer biomarker. AABH has been detected by immunohistochemical staining (IHC) in a broad range of cancers including Prostate Adenocarcinoma through out the world. AABH have been detected by IHC in more than 97% of tumor specimens tested (n > 200) while absent in normal and non cancer tissue. We have developed a sandwich ELISA test for the detection of AABH in serum samples. Preliminary results showed an accuracy of 91- 94% for detecting cancer patients from non-cancer patients in different types of Cancer. Here we have utilized this assay to detect AABH levels in the sera of patients diagnosed with Prostate cancer (biopsy proven, pre-treatment samples), compared to non-cancer individuals. Results: AABH was detected above a threshold level of 1.2 ng/mL in 91% of the sera of PC patients (n = 60), in all different stages and grades of Prostate Cancer. All non-cancer individuals (n = 30) had AABH values below the threshold. Further study of direct comparison of AABH to PSA levels (n = 4,000) is underway. Conclusions: Our data suggest that measurement of serum AABH levels may help to detect Prostate Cancer in early stage and potentially reduce the number of prostate biopsies performed due to increased high serum PSA.

SUN-P100: Tomato Intake, Gleason Score, and Prostate Specific Antigen in Prostate Cancer Patients

2017 ◽  
Vol 36 ◽  
pp. S91
Author(s):  
I. Paur ◽  
M.H. Carlsen ◽  
W. Lilleby ◽  
N. Bolstad ◽  
T. Bjoro ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Gleason Score ◽  
Specific Antigen

scholarly journals RELATIONSHIP BETWEEN P53 EXPRESSION AND PSA SERUM

2012 ◽  
Vol 19 (2) ◽  
Author(s):  
Ahmad Zulfan Hendri ◽  
Danarto HR
Keyword(s):  
Prostate Cancer ◽  
Serum Level ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Immunohistochemical Staining ◽  
Specific Antigen ◽  
P53 Expression ◽  
The Mean ◽  
The Relationship ◽  
Anatomical Pathology

Objective: To know the relationship between p53 expression and prostate specific antigen (PSA) serum level in prostate cancer patients. Material & method: Specimens were studied from patients with pathological diagnosis of prostate cancer in Sardjito Hospital Yogyakarta during 2007 to 2008. The p53 expression was measured by immunohistochemical staining. The stains were done in Department of Anatomical Pathology and examined by a pathologist. The relationship between p53 mutated expression and PSA serum level were analyzed with correlation coefficient (rs). Results: There were 29 patients included in this study. The mean age was 66,34 ± 8,15 (50 - 83) years old. The mean PSA serum level was 165,98 ± 269,208 (1,4 – 1051) ng/ml. The mean number of p53 expression was 111,38 ± 94,30 (16 – 396). There was positive correlation between p53 expression and increasing PSA serum level in the prostate cancer patients (rs + 0,497; p = 0,006). Conclusion: P53 expression was positively correlated with increasing PSA serum level.Keywords: Prostate cancer, p53 expression, PSA serum level.

scholarly journals Correlation Between PSA Density and Gleason Score In Prostate Cancer Patients

2020 ◽  
Vol 23 (2) ◽  
pp. 164-168
Author(s):  
Md Naved Yusuf ◽  
Sudip Das Gupta ◽  
Mohammed Mianur Rahman ◽  
Md Mahmud Ur Rahman
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Histological Grade ◽  
Specific Antigen ◽  
Cross Sectional Study ◽  
Continuous Variables ◽  
Cross Sectional ◽  
Psa Density ◽  
The Mean

Background: Prostate cancer is the most common form of malignancy and the second leading cause of cancer death among men. The histological grade is an independent determinant of disease prognosis and survival. The Gleason System (GS) grading is the most widely accepted classification. Several recent studies have searched for factors that could predict GS upgrading. High prostate specific antigen density (PSAD) has been shown to be predictors of risk progression in many studies, reflecting the possibility of undetected aggressive cancer. Objective: To detect the association between PSA density and Gleason score in prostate cancer patients. Methodology: This cross sectional study was carried out at the department of urology, Sir Salimullah Medical College Mitford hospital, Dhaka. Patients diagnosed as prostate cancer meeting the inclusion criteria admitted in the above mentioned place was the study population. Statistical analyses were carried out by using the Statistical Package for Social Sciences version 23.0 for Windows (SPSS Inc., Chicago, Illinois, USA). Student t-test was used for continuous variables. Pearson’s correlation coefficient was used to test the relationship between the groups. P values <0.05 was considered as statistically significant. Results: Total eighty three patients were included in this study. The mean age was found 69.2±7.7 years ranging from 50 to 85 years. The mean volume of prostate was 42.3±17.6 ml ranging from 13.0 to 68.0 ml. The mean Gleason score was 7.8±1.4 ranging from 6.0 to 10.0. More than one third (33.7%) patients had PSA density 0.15- 0.5 ng/ml/ml. Three patients had found Gleason score 9 (5+4) within PSA density 0.51-1.0 ng/ml/ml, 5 patients within PSA density 1.1-1.5 ng/ml/ml, 3 patients within PSA density 1.51-2.0 ng/ml/ml, 6 patients within PSA density 2.1-2.5 ng/ml/ml, 5 patients within PSA density 2.51-3.0 ng/ml/ml and 2 patients within PSA density >3.0 ng/ml/ml. The difference was statistically significant (p<0.05) among seven groups. Positive correlation (r=0.717; p=0.001) between PSA density with Gleason score. Conclusion: In this study, we find there is a strong correlation between PSA density and Gleason score. Bangladesh Journal of Urology, Vol. 23, No. 2, July 2020 p.164-168

Sign in / Sign up

Export Citation Format

Share Document